TSVT - 2seventy bio, Inc Forward Price-to-Revenue Multiple

2seventybio.com (TSVT) - corporate logo

2seventy bio, Inc. (TSVT) leads the CAR-T therapy segment for myeloma thanks to its unique drug, Abecma. The forward P/S history reflects market expectations, where the latest parameter stands at 5.40. While the business is currently focusing on monetizing its scientific pipeline, success depends on insurance coverage and biomaterial safety, which directly impact the issuer's final market capitalization.

2seventybio.com - TSVT Projected Price to Revenue (period 07/04/2022 - 05/24/2025)

2seventy bio, Inc - analytical breakdowns and key metrics (TSVT)

- market price and analyst price targets:
Price Chart 2seventy bio|TSVT - Price Target Chart
- market capitalization statistics:
Market Valuation 2seventy bio, Inc|TSVT - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share 2seventy bio|TSVT - Book Value of Business|Market Capitalization to Book Value Ratio 2seventybio.com|TSVT - Company Assets
- debt and solvency information:
Debt to Equity 2seventy bio, Inc.|TSVT - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital 2seventy bio, Inc.|TSVT - Company Cumulative Debt|Debt to Book Value 2seventy bio, Inc|TSVT - Company Long-Term Loans and Borrowings|Company Current Liabilities 2seventy bio|Quick Ratio 2seventybio.com
- financial results and valuation multiples details:
TSVT - Final Profit|Projected Future Earnings 2seventy bio, Inc.|TSVT - Market Cap to Earnings|Future Price to Earnings 2seventy Bio|TSVT - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple 2seventy bio, Inc|TSVT - Operating profit EBITDA|Earnings per share for the last twelve months 2seventy bio|TSVT - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months 2seventybio.com|TSVT - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year 2seventy bio, Inc.
- revenue and sales proceeds data:
TSVT - Company Revenue|Company Future Sales 2seventy bio|TSVT - P/S Multiple|Market Cap to Future Revenue Ratio 2seventy bio, Inc
Initial company analysis:2seventy bio (TSVT)
Original product of 2seventy bio, Inc

To find a balance between operational risks and return on capital, it is essential to consider the significant pricing power of 2seventy bio, Inc. (TSVT) within the CAR-T therapy segment, where the uniqueness of Abecma renders demand inelastic. The current forward P/S ratio compares the company's market capitalization with its projected annual revenue, allowing investors to gauge market optimism and determine the asset's margin of safety relative to its fundamental value.

Key competitors

Price-to-Projected Revenue Ratio Legend Biotech Corporation LEGN|Sana Biotechnology Inc - Price-to-Projected Revenue Ratio|AUTL: Forward Price-to-Revenue Multiple|Forward Price to Sales ALLO (Allogene Corp)|RNAC: Forward P/S Multiple|Projected Price to Revenue Cellectis CLLS|CRBU (Caribou Biosciences, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Instil Bio Inc. TIL|Price-to-Projected Revenue Ratio Genenta Science S.p.A. (GNTA)|centurytx.com - Market Cap to Projected Revenue|Forward P/S Multiple JSPR (Jasper Therapeutics, Inc.)|Senti Bio (SNTI) - Market Cap to Future Revenue Ratio|ADAP: Forward Price-to-Revenue Multiple|Forward Price to Sales CERO (CERo Therapeutics)|TCRT (alaunos.com) - Forward Price-to-Revenue Multiple|ACHL: Price to Expected Revenue Ratio|CRGX (CARGO Therapeutics) - Forward P/S Multiple|PSTX: Forward Price to Sales|Forward P/S Multiple GRCL